New Alzheimer's drug MK-1167 passes early safety check
NCT ID NCT06285240
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 27 times
Summary
This early-stage study tested a new medicine called MK-1167 in 28 people with Alzheimer's disease who were already taking donepezil. The main goal was to check if MK-1167 is safe and how the body processes it. Researchers measured side effects and drug levels in the blood to guide future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CenExel iResearch, LLC ( Site 0003)
Decatur, Georgia, 30030, United States
-
CenExel iResearch, LLC ( Site 0004)
Savannah, Georgia, 31405, United States
-
Velocity Clinical Research, Hallandale Beach ( Site 0001)
Hallandale, Florida, 33009, United States
Conditions
Explore the condition pages connected to this study.